Topic: Antiviral Pill

Media reports describe surging demand for COVID-19 tests ahead of Christmas as people seek to gather safely. The FDA grants emergency use authorization for Pfizer's antiviral pill, which is touted as 90% effective. The hosts criticize the "psychological operation" of encouraging healthy people to stand in long lines for tests and mock a Canadian PSA featuring a "vaccinated" Rudolph the Red-Nosed Reindeer.

An FDA advisory committee voted 13-10 to recommend EUA for Merck's antiviral pill, Molnupiravir, despite concerns over its 34% efficacy and potential risks during pregnancy. The discussion contrasts the approval of this expensive pill with the suppression of cheaper alternatives like ivermectin.

Merck reported a strong fiscal quarter, exceeding expectations by $1 billion, driven by growth in its oncology business and a 68% increase in Gardasil sales. CEO Robert Davis discussed the upcoming launch of Molnupiravir, an oral antiviral pill intended for home use, with an advisory committee meeting scheduled for late November. Merck plans to produce 10 million courses of the drug by the end of the year, with pricing estimated by some analysts at up to $2,000 per course.